Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Calcium carbonate (13C) is a diagnostic agent labeled with the stable isotope carbon-13, primarily developed for use in non-invasive breath tests to assess gastric acidity. When ingested, the compound reacts with hydrochloric acid (gastric acid) in the stomach to produce calcium chloride, water, and 13C-labeled carbon dioxide (13CO2). The 13CO2 is absorbed into the systemic circulation and eliminated via the lungs. By measuring the ratio of 13CO2 to 12CO2 in exhaled breath using infrared spectroscopy or mass spectrometry, clinicians can estimate gastric pH and acid secretion levels. This methodology is particularly useful for evaluating the efficacy of acid-suppressing therapies, such as proton pump inhibitors (PPIs), and for diagnosing PPI-resistant gastroesophageal reflux disease (GERD).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on calcium carbonate (13C).